Filing search / Inhibrx Biosciences, Inc. / "Corruption"

DEFM14A

INBX Inhibrx Biosciences, Inc.

26 Apr 24

Proxy related to merger

4:06pm

’ compliance with applicable anti-bribery, anti-corruption, anti-money laundering laws and global trade control laws; certain regulatory matters, including … Section 3.17 Environmental A-25 Section 3.18 Suppliers A-25 Section 3.19 Anti-Corruption A-25 Section 3.20 Global Trade Control Laws A-26

DEFA14A

INBX Inhibrx Biosciences, Inc.

23 Jan 24

Additional proxy soliciting materials

6:38am

3.17 Environmental Section 3.18 Suppliers Section 3.19 Anti-Corruption Section 3.20 Global Trade Control Laws Section 3.21 FDA and Related Matters … Anti-Corruption. Since January 1, 2021, neither the Company, nor any Subsidiary of the Company, nor, to the Knowledge of the Company, any director

8-K

EX-2.1

INBX Inhibrx Biosciences, Inc.

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

3.17 Environmental Section 3.18 Suppliers Section 3.19 Anti-Corruption Section 3.20 Global Trade Control Laws Section 3.21 FDA and Related Matters … Anti-Corruption. Since January 1, 2021, neither the Company, nor any Subsidiary of the Company, nor, to the Knowledge of the Company, any director

S-3ASR

EX-1.2

cy5dn7fpg7u8vvul8f0

3 Sep 21

Automatic shelf registration

4:22pm

10-K

uz9h4qb

12 Mar 21

Annual report

8:46am

10-Q

5b0d8k0mw

13 Nov 20

Quarterly report

4:09pm

424B4

859rh

19 Aug 20

Prospectus supplement with pricing info

5:21pm

DRS

m5kgik4pyijkxsl

26 Jun 20

Draft registration statement

12:00am

S-1

2n6uwncs c4g

3 Jun 19

IPO registration

4:17pm

DRS/A

2orz3 qknsew

22 Feb 19

Draft registration statement (amended)

12:00am

DRS

6pess3t

7 Jan 19

Draft registration statement

12:00am